Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/16983
Title: Theranostics of Neuroendocrine Tumors
Authors: Lee, ST;Kulkarni, HR;Singh, A;Baum, RP
Issue Date: Oct-2017
Citation: Visceral Medicine 2017; 33(5): 358-366
Abstract: Somatostatin receptor positron emission tomography/computed tomography using 68Ga-labeled somatostatin analogs is the mainstay for the evaluation of receptor status in neuroendocrine tumors (NETs). This translates towards better therapy options, with increasing evidence of peptide receptor radionuclide therapy (PRRT) as the treatment of choice for advanced or progressive NETs. There are benefits in progression-free and overall survival as well as a significant improvement in clinical condition. In patients with progressive NETs, fractionated, personalized PRRT results in good therapeutic responses with no significant severe hematological and/or renal toxicity, thus improving quality of life.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16983
DOI: 10.1159/000480383
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/29177165
Type: Journal Article
Subjects: Diagnosis
Neuroendocrine tumor, NET
Peptide receptor radionuclide therapy, PRRT
Positron emission tomography/computed tomography, PET/CT
Theranostics
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.